Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: A prospective study

American Journal of Gastroenterology

Volumn 111, Issue 5, 2016, Pages 685-690

  Zenlea, Talia ^a   Yee, Eric U ^a   Rosenberg, Laura ^a   Boyle, Marie ^a   Nanda, Kavinderjit S ^a   Wolf, Jacqueline L ^a   Falchuk, Kenneth R ^a   Cheifetz, Adam S ^a   Goldsmith, Jeffrey D ^a   Moss, Alan C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; COLON RESECTION; COLONOSCOPY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; DRUG DOSE INCREASE; FEMALE; GEBOES SCORE; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; RECURRENCE RISK; REMISSION; RISK FACTOR; STEROID THERAPY; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DIAGNOSTIC IMAGING; ENDOSCOPY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TIME FACTOR;

ADULT; COLITIS, ULCERATIVE; ENDOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS;

EID: 84961233870     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.50     Document Type: Article

References (35)

1. Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2015; 65: 408-14
2. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn?s disease. Clin Gastroenterol Hepatol 2013; 13: 1042-50.e2
3. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-9
4. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis patients with mucosal healing. Gastroenterology 2012; 142: S653
5. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
6. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013; 11: 1601-8
7. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014; 12: 929-34.e2
8. Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of Inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013; 11: 991-6
9. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with Inflammatory bowel disease in clinical remission have mucosal Inflammation. Inflamm Bowel Dis 2012; 18: 1634-40
10. Rosenberg L, Lawlor G, Zenlea T, et al. Predictors of endoscopic Inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2012; 19: 779-84
11. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8
12. Hefti MM, Chessin DB, Harpaz NH, et al. Severity of Inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009; 52: 193-7
13. Rubin D, Huo D, Hetzel J, et al. Increased degree of histological Inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology 2012; 132: A19
14. Bryant RV, Winer S, Travis SP, et al. Systematic review: histological remission in Inflammatory bowel disease. Is ?complete? remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8: 1582-97
15. Theede K, Holck S, Ibsen P, et al. Level of fecal calprotectin correlates wiThendoscopic and histologic Inflammation and identifi es patients with mucosal healing of ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-36
16. Moss AC. Residual Inflammation and ulcerative colitis in remission. Gastroenterol Hepatol (N Y) 2014; 10: 181-3
17. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998; 43: 29-32
18. Higgins PD, Schwartz M, Mapili J, et al. Patient defi ned dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9
20. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of Inflammation in ulcerative colitis. Gut 2000; 47: 404-9
21. Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014; 20: 564-75
22. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in Inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22
23. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic Inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-105
24. Korelitz BI, Sultan K, Kothari M, et al. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014; 20: 4980-6
25. Geboes K, Rutgeerts P, Olson A, et al. Infliximab treatment results in the reduction of Inflammation and Inflammatory markers in the mucosa of patients with ulcerative colitis: the ACT 1 trial experience. Gut 2005; 54: A62
26. Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 2011; 17: 194-8
27. Iacucci M, Fort Gasia M, Hassan C, et al. Complete mucosal healing defi ned by endoscopic Mayo subscore still demonstrates abnormalities by novel high defi nition colonoscopy and refi ned histological gradings. Endoscopy 2015; 47: 726-34
28. Feagan BG, Sandborn WJ, D?Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-157.e2
29. Zeissig S, Bergann T, Fromm A, et al. Altered ENaC expression leads to impaired sodium absorption in the noninfl amed intestine in Crohn?s disease. Gastroenterology 2008; 134: 1436-47
30. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn?s disease. Gut 1996; 39: 684-9
31. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin identifi es histologic Inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol 2014; 12: 1865-70
32. Molander P, Farkkila M, Ristimaki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFalpha-blocking agents in Inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015; 9: 33-40
33. Bressenot A, Salleron J, Bastien C, et al. Comparing histological activity indexes in UC. Gut 2014; 64: 1412-8
34. D?Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and Efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86
35. Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-Effective endpoint for biologic therapy in Crohn?s disease? A decision analysis. Inflamm Bowel Dis 2013; 19: 37-44